In short
Clinical trials are investigating Asciminib in people with chronic myeloid leukemia, including children and adults. These studies look at safety, dose, and treatment response in different patient groups. They help show how Asciminib performs in pediatric patients and in adults with chronic phase CML after prior treatments.
Key points
- Clinical trials of Asciminib are being done in chronic myeloid leukemia, especially chronic phase disease. One study is a Phase 1 trial in children and teens with Philadelphia chromosome positive CML-CP to find the right pediatric dose and check safety through pharmacokinetic measures. Another is a Phase 3 trial in adults with CML-CP who already had at least two tyrosine kinase inhibitors and did not have major molecular response at the start. The adult study looked at major molecular response at 48 weeks. Together, these studies focus on both early dose finding and later treatment response in different patient groups.
Clinical trials overview
These studies are investigating Asciminib in people with chronic myeloid leukemia (CML), a blood cancer that affects the bone marrow and blood. The trials focus on the chronic phase of the disease, which is an earlier stage of CML. One study is in children and teens, while the other is in adults who already had previous treatment with tyrosine kinase inhibitors, or TKIs.
Pediatric dose and safety study
The first study is a Phase 1 trial in pediatric patients with Philadelphia chromosome positive CML in chronic phase, also written as Ph+ CML-CP. It is authorised and plans to enroll 40 patients. The main goal is to characterize the pharmacokinetic profile of Asciminib in children, which means seeing how the body handles the medicine over time.
This study also aims to identify a pediatric formulation dose taken with food that gives exposure similar to 40 mg twice daily in adults who are fasting. In simple terms, the researchers want to find a child dose that leads to a blood level pattern close to the adult reference dose used in the study plan.
Adult treatment optimization study
The second study is a Phase 3 trial in adults with CML-CP and is completed. It enrolled 203 patients and studied treatment optimization in people who had already received two or more prior TKI treatments. Patients also had no evidence of major molecular response at baseline, which means the cancer markers were not yet showing that deep level of response at the start of the study.
The main goal was to estimate the major molecular response rate at week 48. This tells researchers how many patients reached a strong treatment response after nearly one year of follow-up.
What the trials measure
The pediatric study uses PK endpoints, which are measurements that show how much drug is in the body and for how long. The primary PK measures are AUClast and AUCtau, and the secondary PK measures are Cmax, Tmax, and Ctrough. These terms help researchers understand total exposure, peak level, time to peak, and the lowest level before the next dose.
The adult study uses MMR at 48 weeks as the primary outcome. MMR stands for major molecular response, a test result that shows a deep drop in leukemia markers. This endpoint helps show whether treatment is working well over time in people who had already been treated before.
Who can join these studies
The pediatric trial is for pediatric patients with Ph+ CML-CP who were previously treated with one or more TKIs. This means the study is not for newly diagnosed children only; it is for young patients who already had treatment before.
The adult trial is for people with CML-CP who had at least two prior TKI treatments and no MMR at baseline. This group represents patients with earlier treatment experience who still need better disease control.
What the trial phases mean
Phase 1 studies usually come first and often focus on dose finding and safety in a smaller group of patients. That is why the pediatric study is centered on drug exposure and dose selection.
Phase 3 studies are later-stage trials and usually involve more patients to better understand how well a treatment works. That is why the adult study looks at response at 48 weeks in a larger group of 203 patients.